Orticumab

Names

[ Name ]:
Orticumab

Biological Activity

[Description]:

Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

[In Vitro]

Orticumab (10 μg/mL；24 小时) 增加 oxLDL 刺激后体外培养的 PBMC 中的 CD14+ ICOS-L+ 群体[1]。

[In Vivo]

Orticumab (10 毫克/小鼠；腹腔注射；每周一次，持续 3 周) 减少主动脉弓中的动脉粥样硬化，减少 CD68 巨噬细胞瓣膜下斑块染色[1]。 Animal Model: B6.lpr.ApoE-/- mice (18-week-old) fed with high-fat diet (HFD)[1] Dosage: 10 mg/mouse Administration: Intraperitoneal injection; once weekly for 3 weeks Result: Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%.

[References]

[1]. Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863.

[2]. Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05.

Chemical & Physical Properties

No Any Chemical & Physical Properties